FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013969002> ?p ?o ?g. }

• W2013969002 endingPage "342" @default.
• W2013969002 startingPage "332" @default.
• W2013969002 abstract "Liver X receptor (LXR) agonists have the potential to treat atherosclerosis based on their ability to enhance reverse cholesterol transport. However, their side effects, such as induction of liver lipogenesis and triglyceridemia, may limit their pharmaceutical development. In contrast to the nonsteroidal LXR agonist <i>N</i>-(2,2,2-trifluoroethyl)-<i>N</i>-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide (T0901317), 3α, 6α, 24-trihydroxy-24, 24-di(trifluoromethyl)-5β-cholane (ATI-829), a novel potent synthetic steroidal LXR agonist, was a poor inducer of sterol regulatory element-binding protein 1c expression in hepatoma HepG2 cells, whereas both compounds increased ABCA1 expression in macrophage THP-1 cells. In male low-density lipoprotein receptor-deficient mice, ATI-829 selectively activated LXR target gene expression in mouse intestines and macrophages but not in the liver. A significant increase in liver triglyceride and plasma triglyceriderich small very low-density lipoprotein (VLDL) was observed in T0901317 but not ATI-829-treated mice. Compared with vehicle-treated mice, atherosclerosis development was significantly inhibited in the innominate artery after treatment with either compound. However, in the aortic root, inhibition of atherosclerosis was only observed in the right (right coronary artery-associated sinus) but not the left coronary-related sinus (left coronary artery-associated sinus; LC) of mice treated with either compound. Lesions in the innominate artery were less complex after treatment with either compound and contained mostly macrophage foam cells. In contrast, LC lesions were more complex and had a large collagen-positive fibrous cap and less macrophage foam cell area after treatment with either compound. The T0901317-induced hypertriglyceridemia was accompanied by an increase in small triglyceride-rich VLDL that may influence LXR agonist-mediated antiatherosclerotic effects at certain vascular sites. ATI-829, by selectively activating LXR in certain tissues without inducing hypertriglyceridemia, is a good candidate for drug development." @default.
• W2013969002 created "2016-06-24" @default.
• W2013969002 creator A5012805315 @default.
• W2013969002 creator A5021558137 @default.
• W2013969002 creator A5034961712 @default.
• W2013969002 creator A5039980957 @default.
• W2013969002 creator A5046992424 @default.
• W2013969002 creator A5059544618 @default.
• W2013969002 creator A5081561796 @default.
• W2013969002 date "2008-08-22" @default.
• W2013969002 modified "2023-10-16" @default.
• W2013969002 title "Antiatherosclerotic Effects of a Novel Synthetic Tissue-Selective Steroidal Liver X Receptor Agonist in Low-Density Lipoprotein Receptor-Deficient Mice" @default.
• W2013969002 cites W1607230014 @default.
• W2013969002 cites W1650965741 @default.
• W2013969002 cites W1966373116 @default.
• W2013969002 cites W1975070287 @default.
• W2013969002 cites W1976205910 @default.
• W2013969002 cites W1979983012 @default.
• W2013969002 cites W1993115089 @default.
• W2013969002 cites W1996168740 @default.
• W2013969002 cites W1998308002 @default.
• W2013969002 cites W2016019844 @default.
• W2013969002 cites W2021926309 @default.
• W2013969002 cites W2022996249 @default.
• W2013969002 cites W2026587556 @default.
• W2013969002 cites W2030442022 @default.
• W2013969002 cites W2034911894 @default.
• W2013969002 cites W2039664177 @default.
• W2013969002 cites W2050412627 @default.
• W2013969002 cites W2058205407 @default.
• W2013969002 cites W2079416900 @default.
• W2013969002 cites W2085909854 @default.
• W2013969002 cites W2106169706 @default.
• W2013969002 cites W2113868526 @default.
• W2013969002 cites W2119343066 @default.
• W2013969002 cites W2125674758 @default.
• W2013969002 cites W2127308854 @default.
• W2013969002 cites W2128616258 @default.
• W2013969002 cites W2128660079 @default.
• W2013969002 cites W2129471397 @default.
• W2013969002 cites W2139664489 @default.
• W2013969002 cites W2150223591 @default.
• W2013969002 cites W2151211162 @default.
• W2013969002 cites W2152311269 @default.
• W2013969002 cites W2153673003 @default.
• W2013969002 cites W2162849831 @default.
• W2013969002 cites W2163484110 @default.
• W2013969002 cites W2165104851 @default.
• W2013969002 cites W2165894715 @default.
• W2013969002 cites W2530251551 @default.
• W2013969002 cites W4231888801 @default.
• W2013969002 cites W4240591859 @default.
• W2013969002 cites W4297993676 @default.
• W2013969002 doi "https://doi.org/10.1124/jpet.108.142687" @default.
• W2013969002 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2574974" @default.
• W2013969002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18723776" @default.
• W2013969002 hasPublicationYear "2008" @default.
• W2013969002 type Work @default.
• W2013969002 sameAs 2013969002 @default.
• W2013969002 citedByCount "60" @default.
• W2013969002 countsByYear W20139690022012 @default.
• W2013969002 countsByYear W20139690022013 @default.
• W2013969002 countsByYear W20139690022014 @default.
• W2013969002 countsByYear W20139690022015 @default.
• W2013969002 countsByYear W20139690022017 @default.
• W2013969002 countsByYear W20139690022018 @default.
• W2013969002 countsByYear W20139690022019 @default.
• W2013969002 countsByYear W20139690022020 @default.
• W2013969002 countsByYear W20139690022021 @default.
• W2013969002 countsByYear W20139690022022 @default.
• W2013969002 countsByYear W20139690022023 @default.
• W2013969002 crossrefType "journal-article" @default.
• W2013969002 hasAuthorship W2013969002A5012805315 @default.
• W2013969002 hasAuthorship W2013969002A5021558137 @default.
• W2013969002 hasAuthorship W2013969002A5034961712 @default.
• W2013969002 hasAuthorship W2013969002A5039980957 @default.
• W2013969002 hasAuthorship W2013969002A5046992424 @default.
• W2013969002 hasAuthorship W2013969002A5059544618 @default.
• W2013969002 hasAuthorship W2013969002A5081561796 @default.
• W2013969002 hasBestOaLocation W20139690022 @default.
• W2013969002 hasConcept C104317684 @default.
• W2013969002 hasConcept C110459506 @default.
• W2013969002 hasConcept C126322002 @default.
• W2013969002 hasConcept C134018914 @default.
• W2013969002 hasConcept C167400880 @default.
• W2013969002 hasConcept C170493617 @default.
• W2013969002 hasConcept C185592680 @default.
• W2013969002 hasConcept C2778163477 @default.
• W2013969002 hasConcept C2778938600 @default.
• W2013969002 hasConcept C2780072125 @default.
• W2013969002 hasConcept C55493867 @default.
• W2013969002 hasConcept C63932345 @default.
• W2013969002 hasConcept C71924100 @default.
• W2013969002 hasConcept C86339819 @default.
• W2013969002 hasConcept C86803240 @default.
• W2013969002 hasConceptScore W2013969002C104317684 @default.
• W2013969002 hasConceptScore W2013969002C110459506 @default.
• W2013969002 hasConceptScore W2013969002C126322002 @default.

• next